{
    "Clinical Trial ID": "NCT01569087",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Empegfilgrastim 3 mg",
        "  Patients will receive a single administration of empegfilgrastim at a dose of 3 mg subcutaneously , 24 h after the chemotherapy",
        "  empegfilrastim: Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 3 or 6 mg.",
        "INTERVENTION 2: ",
        "  Empegfilgrastim 6 mg",
        "  Patients will receive a single administration of empegfilgrastim at a dose of 6 mg subcutaneously, 24 h after the chemotherapy",
        "  empegfilrastim: Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 3 or 6 mg."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Signed informed consent form;",
        "  Histologically verified diagnosis of stage IIb/III/IV breast cancer;",
        "  Age of 18-70 years inclusive;",
        "  If the patient had received the chemotherapy for breast cancer, it should be finished 30 days before the beginning of the study;",
        "  ECOG Performance Status of 0, 1 or 2, not increasing within during 2 weeks before randomization;",
        "  ANC level of 1500/\u03bcL and more at the beginning of the study",
        "  Platelet count of 100 000/\u03bcL and more at the beginning of the study",
        "  Hemoglobin level of 90 g/l and more",
        "  Creatinine level <1.5 mg/dl",
        "  Total bilirubin level <1.5 \u00d7 the upper limit of normal (ULN)",
        "  ALT and/or AST levels <2.5\u00d7ULN (5\u00d7ULN for patients with liver metastases);",
        "  Alkaline phosphatase <5\u00d7ULN;",
        "  Left ventricular ejection fraction >50% and more;",
        "  If the patient had received adjuvant and/or neoadjuvant therapy, the cumulative dose of anthracyclines should not exceed 500 mg/m2 for doxorubicin or 500 mg/m2 for epirubicin;",
        "  Ability of the participant to follow the protocol requirements, according to the Investigator's opinion;",
        "  Patients of childbearing potential must implement reliable contraceptive measures during the study treatment, starting 4 weeks prior randomization and for 6 months after the last administration of the study drug.",
        "Exclusion Criteria:",
        "  Patient has received two or more chemotherapy regimens for the metastatic breast cancer;",
        "  Documented hypersensitivity to filgrastim, pegfilgrastim, docetaxel, doxorubicin, dexamethasone and/or its excipients, PEGylated drugs, recombinant proteins.",
        "  Pregnancy or breastfeeding;",
        "  Systemic antibiotic therapy within 72 h prior empegfilgrastim/filgrastim administration;",
        "  Concomitant radiotherapy (except selective radiotherapy of bone metastases);",
        "  Surgery, radiotherapy (except selective radiotherapy of bone metastases), administration of any experimental drugs within 30 days prior randomization;",
        "  History of bone marrow/stem cell transplantation;",
        "  Conditions limiting the patient's ability to follow the protocol;",
        "  CTCAE grade 2/4 neuropathy",
        "  HIV, HCV, HBV, T.Pallidum infection(s);",
        "  Acute or active chronic infections."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  CTCAE Grade 3/4 Neutropenia Incidence",
        "  [Not Specified]",
        "  Time frame: 21 days",
        "Results 1: ",
        "  Arm/Group Title: Empegfilgrastim 3 mg",
        "  Arm/Group Description: Patients will receive a single administration of empegfilgrastim at a dose of 3 mg subcutaneously , 24 h after the chemotherapy",
        "  empegfilrastim: Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 3 or 6 mg.",
        "  Overall Number of Participants Analyzed: 21",
        "  Measure Type: Number",
        "  Unit of Measure: participants  18",
        "Results 2: ",
        "  Arm/Group Title: Empegfilgrastim 6 mg",
        "  Arm/Group Description: Patients will receive a single administration of empegfilgrastim at a dose of 6 mg subcutaneously, 24 h after the chemotherapy",
        "  empegfilrastim: Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 3 or 6 mg.",
        "  Overall Number of Participants Analyzed: 20",
        "  Measure Type: Number",
        "  Unit of Measure: participants  13"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 0/21 (0.00%)",
        "  neutropenia grade 4 0/21 (0.00%)",
        "Adverse Events 2:",
        "  Total: 0/20 (0.00%)",
        "  neutropenia grade 4 0/20 (0.00%)"
    ]
}